Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of inhaled treprostinil palmitil powder in pulmonary hypertension associated with interstitial lung disease
MOH_2025-11-10_015450Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing TPIP with Placebo (2 arms). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on MOH_2025-11-10_015450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-10_015450.